retatrutide type 2 diabetes phase 2 results 2024 2025 🚨 Today, retatrutide, the GIP/GLP-1/glucagon triple agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ Retatrutide: A Promising Option for

Tirzepatide microdosing example Strategy A: Titration with smaller increments (compounded version) Tirzepatide come in the form of prefilled pens in fixed, single-use doses (e.g., 2.5 mg, 5 mg, etc.)

While SURPASS-4 was not powered to evaluate differences in MACE-4 incidence between tirzepatide treatment groups and glargine, it was designed to fulfill the MACE-4 non-inferiority analysis requested by regulatory authorities to evaluate the cardiovascular safety of new glucose lowering medications

JACC 75(17):20992106 Patel KHK, Rohin KR, Arunashis S, Pavidra S, Maddalena A, Fu SN (2022) Obesity as a risk factor for cardiac arrhythmias

Individual response varies some patients lose 20% on semaglutide

The broader guide on tirzepatide and autoimmune disease provides additional context

Meanwhile, pharmaceutical giants Novo Nordisk and Eli Lilly have gone on the offensive, filing dozens of lawsuits in multiple states against medical spas, weight-loss clinics and pharmacies